Cogent Biosciences (COGT) Assets Average (2018 - 2026)

Cogent Biosciences (COGT) has 9 years of Assets Average data on file, last reported at $920.3 million in Q1 2026.

• On a quarterly basis, Assets Average rose 200.9% year-over-year to $920.3 million in Q1 2026; TTM through Mar 2026 was $920.3 million, a 200.9% increase from a year earlier, with the FY2025 full-year figure at $632.8 million, up 97.32% from the prior year.
• Assets Average for Q1 2026 stood at $920.3 million, up from $681.8 million in the prior quarter.
• Over the last five years, Assets Average for COGT reached as high as $920.3 million in Q1 2026 and fell as low as $219.5 million in Q1 2022.
• Historically, Assets Average has averaged $390.4 million across 5 years, with a median of $348.8 million in 2022.
• Across the five-year window, Assets Average plunged 38.35% in 2025 and jumped 200.9% in 2026, its largest moves.
• Year by year, Assets Average stood at $316.2 million in 2022, then gained by 5.77% to $334.4 million in 2023, then advanced by 6.43% to $356.0 million in 2024, then soared by 91.53% to $681.8 million in 2025, then jumped by 34.99% to $920.3 million in 2026.
• Per Business Quant data, the three most recent Assets Average figures were $920.3 million in Q1 2026, $681.8 million in Q4 2025, and $350.4 million in Q3 2025.